Open AccessLack of Synergy Between β-Agonist Treatment and a Blockage of Sarcoplasmic Calcium Flow in a Rat Cancer Cachexia Model
Author(s) -
Sílvia Busquets,
Marta Castillejo,
Queralt Jové,
Baptiste Jude,
Patricia Mejías,
Francisco J. LópezSoriano,
Josep Μ. Argilés
Publication year - 2021
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s293834
Subject(s) - dantrolene , medicine , cachexia , formoterol , malignant hyperthermia , ryr1 , agonist , saline , weight loss , endocrinology , adipose tissue , calcium , cancer , anesthesia , ryanodine receptor , obesity , receptor , budesonide , corticosteroid
During cancer cachexia, both skeletal muscle and adipose tissue losses take place. The use of β2-agonists, formoterol in particular, has proven to be very successful in the treatment of the syndrome in pre-clinical models. The object of the present research was to study the effects of a combination of formoterol and dantrolene, an inhibitor of the ryanodine receptor 1 (RyR1), on body weight loss and cachexia in tumour-bearing animals.